Mangoceuticals (MGRX) Fundamental Analysis: Revenue, Earnings & Valuation

1.82 / 10

Underperform

Fundamental rating is Underperform with a 1.8/10 score. Strengths include accounts receivable turnover and interest coverage, while revenue YoY drops 29% and tax-to-profit is zero, dragging performance. Overall, the financial health is subpar and warrants caution.

Analysis Checks(6/10)

Revenue-MV

Value-3.64

Score1/3

Weight27.88%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value-29.17

Score1/3

Weight-6.41%

1M Return-1.40%

Inventory turnover ratio

Value47.57

Score3/3

Weight-2.99%

1M Return-0.67%

Accounts receivable turnover ratio

Value25.89

Score2/3

Weight-2.96%

1M Return-0.65%

PB-ROE

Value-0.38

Score1/3

Weight27.89%

1M Return5.22%

Income tax / Total profit (%)

Value0.00

Score0/3

Weight-6.72%

1M Return-1.54%

Fixed assets turnover ratio

Value148.99

Score3/3

Weight3.93%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-3.34%

1M Return-0.73%

Cost of sales ratio (%)

Value43.89

Score2/3

Weight-3.28%

1M Return-0.74%

Asset-MV

Value-0.48

Score2/3

Weight65.98%

1M Return9.91%

Is MGRX undervalued or overvalued?

MGRX scores 1.82/10 on fundamentals and holds a Premium valuation at present. Backed by its -126.42% ROE, -4245.52% net margin, -0.30 P/E ratio, 0.38 P/B ratio, and 55.99% earnings growth, these metrics solidify its Underperform investment rating.